News for Immunic Inc Stock (IMUX)

Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

PRNewsWire • 04/13/21

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838

PRNewsWire • 03/31/21

Immunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect

Benzinga • 03/24/21

7 Beaten Down Stocks With Insider Buying

InvestorPlace • 03/23/21

Immunic, Inc. to Participate in Industry and Investor Conferences in March

PRNewsWire • 03/02/21

Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity

PRNewsWire • 02/26/21

Immunic's IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease Study

Benzinga • 02/18/21

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

PRNewsWire • 02/18/21

IMU-838 Data In COVID-19 Study Fails To Cheer Immunic Investors; Stock Tanks

Benzinga • 02/17/21

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

PRNewsWire • 02/17/21

Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25

PRNewsWire • 02/11/21

Immunic, Inc. to Participate in Investor Conferences in January

PRNewsWire • 01/05/21

Immunic, Inc. Added to NASDAQ Biotechnology Index

PRNewsWire • 12/14/20

Immunic, Inc. to Participate in Investor Conferences in December

PRNewsWire • 11/24/20

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

PRNewsWire • 11/17/20

Immunic, Inc. to Participate in Investor and Scientific Conferences in November

PRNewsWire • 11/10/20

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

PRNewsWire • 11/02/20

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

PRNewsWire • 10/20/20

Immunic, Inc. to Participate in Scientific Conferences in October

PRNewsWire • 09/29/20

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19

PRNewsWire • 09/28/20

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

PRNewsWire • 09/11/20

Immunic, Inc. to Participate in Scientific and Investor Conferences in September

PRNewsWire • 09/08/20

Why Immunic Stock Is Soaring Today

The Motley Fool • 08/26/20

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

PRNewsWire • 08/20/20

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares

PRNewsWire • 08/10/20